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Medical treatment of primary sclerosing cholangitis: A role for
novel bile acids and other (post-)transcriptional modulators?
Abstract
Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic disease of the liver and bile ducts that
is associated with inflammatory bowel disease, generally leads to end-stage liver disease, and is
complicated by malignancies of the biliary tree and the large intestine. The pathogenesis of PSC remains
enigmatic, making the development of targeted therapeutic strategies difficult. Immunosuppressive and
antifibrotic therapeutic agents were ineffective or accompanied by major side effects. Ursodeoxycholic
acid (UDCA) has consistently been shown to improve serum liver tests and might lower the risk of
colon carcinoma and cholangiocarcinoma by yet unknown mechanisms. Whether "high dose" UDCA
improves the long-term prognosis in PSC as suggested by small pilot trials remains to be demonstrated.
The present overview discusses potential therapeutic options aside of targeted immunological therapies
and UDCA. The C23 bile acid norUDCA has been shown to markedly improve biochemical and
histological features in a mouse model of sclerosing cholangitis without any toxic effects. Studies in
humans are eagerly being awaited. Nuclear receptors like the farnesoid-X receptor (FXR), pregnane-X
receptor (PXR), vitamin D receptor (VDR), and peroxisome-proliferator-activator receptors (PPARs)
have been shown to induce expression of diverse carriers and biotransformation enzymes of the
intestinal and hepatic detoxification machinery and/or to modulate fibrogenesis. Pros and cons of
respective receptor agonists for the future treatment of PSC are discussed in detail. In our view, the
novel bile acid norUDCA and agonists of PPARs, VDR, and PXR appear particularly attractive for
further studies in PSC.
Beuers et al.: Future treatment of PSC 
Clinical Reviews in Allergy and Immunology 2008 
In press 
Medical treatment of primary sclerosing cholangitis: 
A role for novel bile acids and other (post-)transcriptional 
modulators? 
 
Ulrich Beuers1, Gerd A. Kullak-Ublick2, Thomas Pusl3, Erik R. Rauws1, Christian Rust3 
 
Department of Gastroenterology & Hepatology, Academic Medical Center,  
University of Amsterdam, The Netherlands 
Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, 
University Hospital Zurich, Switzerland 
Department of Medicine II, Klinikum Grosshadern, University of Munich, Germany 
 
Address for correspondence: Ulrich Beuers, M.D. 
     Professor of Gastroenterology & Hepatology 
     Department of Gastroenterology & Hepatology, G4-213 
     Academic Medical Center, University of Amsterdam 
     P.O.Box 22700 
     1100 DE Amsterdam 
The Netherlands 
     tel.: +31-20-56 62422 
     fax: +31-20-69 17033 
     email: u.h.beuers@amc.uv.nl 
Beuers et al.: Future treatment of PSC 
 
 
2 
Abstract 
Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic disease of liver and bile 
ducts that is associated with inflammatory bowel disease, generally leads to end-stage liver 
disease and is complicated by malignancies of the biliary tree and the large intestine. The 
pathogenesis of PSC remains enigmatic making the development of targeted therapeutic 
strategies difficult. Immunosuppressive and antifibrotic therapeutic agents were ineffective or 
accompanied by major side effects. Ursodeoxycholic acid (UDCA) has consistently been 
shown to improve serum liver tests and might lower the risk of colon carcinoma and 
cholangiocarcinoma by yet unknown mechanisms. Whether “high dose” UDCA improves the 
long-term prognosis in PSC as suggested by small pilot trials remains to be demonstrated. The 
present overview discusses potential therapeutic options aside of targeted immunological 
therapies and UDCA. The C23 bile acid norUDCA has been shown to markedly improve 
biochemical, and histological features in a mouse model of sclerosing cholangitis without any 
toxic effects. Studies in humans are eagerly being awaited. Nuclear receptors like the 
farnesoid-X receptor (FXR), pregnane-X receptor (PXR), vitamin D receptor (VDR), and 
peroxisome-proliferator-activator receptors (PPARs) have been shown to induce expression of 
diverse carriers and biotransformation enzymes of the intestinal and hepatic detoxification 
machinery and/or to modulate fibrogenesis. Pro’s and con’s of respective receptor agonists for 
the future treatment of PSC are discussed in detail.  In our view, the novel bile acid norUDCA 
and agonists of PPAR’s, VDR, and PXR appear particularly attractive for further studies in 
PSC. 
 
 
 
BACKGROUND  
Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic disorder of the liver and bile 
ducts that is characterized by fibrosing inflammation of the intra- and/or extrahepatic biliary 
tree generally leading to progressive bile duct obstruction, fibrosis, cirrhosis and end-stage 
liver disease 1. Twice as many men as women are affected. PSC is diagnosed most frequently 
between ages 25 and 40 years. Criteria for the diagnosis of PSC include (i) a cholestatic serum 
enzyme pattern, (ii) typical cholangiographic findings of bile duct stenoses and dilatations, 
(iii) histologic findings compatible with PSC showing mild to moderate portal inflammation, 
and (iv) exclusion of secondary causes of sclerosing cholangitis. The characteristic 
histological finding of an onion skin-like fibrosis around bile ductules in PSC is only found in 
a minority of conventional liver biopsies in patients with PSC as bile ducts with a diameter > 
100  m are generally affected by the fibrosing inflammatory process. Secondary changes 
may rather predominate around smaller ductules. Concomitant inflammatory bowel disease, 
mainly ulcerative colitis (UC) is found in 70-90% of the patients and atypical perinuclear 
antineutrophil cytoplasmatic antibodies (pANCA) are detected in more than 70% of patients 1.  
 
The pathogenesis of PSC remains enigmatic making the development of targeted therapeutic 
strategies almost impossible 2, 3. Adams & Ekstein provided the attractive hypothesis that PSC 
is mediated by long-lived gut-derived mucosal T-cells that are normally restricted to the gut 
and that are recruited to the portal tracts of the liver by aberrantly expressed endothelial cell 
adhesion molecules (like the gut addressin MADCAM-1) and gut-specific chemokines (like 
CCL25) in individuals susceptible to PSC 4. Modulation of tissue specific lymphocyte homing 
appears as an attractive therapeutic approach in the future if this hypothesis can be confirmed 
by further studies. The present article does not address potential future targeted 
immunological approaches and refers to detailed expert reviews 2, 4. 
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Primary sclerosing cholangitis, like other chronic cholestatic liver diseases, is characterized 
by hepatic retention of potentially toxic substances normally excreted into bile, in particular 
hydrophobic bile acids, as a consequence of impaired hepatobiliary secretion and/or 
obstruction of bile flow 5, 6. Elevated levels of bile acids in the hepatocyte 7 then can lead to 
cellular injury by hepatocyte apoptosis and necrosis and eventually to liver failure and the 
need for liver transplantation 8. Therefore, bile acid homeostasis is tightly controlled. The 
proteins responsible for synthesis, metabolism, conjugation and transport of bile acids are 
regulated in a coordinated fashion by nuclear hormone receptors including the farnesoid X 
receptor (FXR; NR1H4), the pregnane X receptor (PXR; NR1I2), the constitutive androgen 
receptor (CAR; NR1I3), the vitamin D receptor (VDR) and the peroxisome-proliferator-
activator receptor γ (PPAR γ; NR1C1) 9, 10. Since the intrinsic adaptive responses to 
cholestasis tend to reduce hepatic concentration of bile acids but usually are not sufficient, 
pharmacological agents which augment the adaptive responses may be beneficial. The nuclear 
receptors therefore have been proposed as potential targets for pharmacological treatment of 
cholestasis 6, 10-12.  
 
Patients with PSC have an increased risk of developing carcinomas of the biliary tree (in the 
largest cohort studied (n=604): 161-fold in comparison to a matched healthy Swedish 
population), pancreas (14-fold), and colon (10-fold) 13. Both, genetic 14, 15 and environmental 
factors are discussed to contribute to carcinogenesis in this patient group. Among the tumors 
observed in PSC, colon carcinoma is by far the most frequent in the general population (5-6% 
lifetime risk) and also determines the prognosis of a considerable rate of patients with PSC 
and associated ulcerative colitis (UC). Colorectal dysplasia/carcinoma has been reported to 
develop in up to 50% of PSC/UC patients during 25-year follow-up 16 and has been shown to 
be a major cause of death in PSC patients after liver transplantation 17-19. 70-90% of patients 
with PSC suffer from inflammatory bowel disease, mainly ulcerative colitis (UC) which itself 
is a risk factor for development of colorectal neoplasia. However, the presence of UC does not 
alone explain the increased risk of colon carcinoma  in patients with PSC as patients with PSC 
and UC have a significantly higher risk to develop colon dysplasia/carcinoma when compared 
to patients with UC only (meta-analysis: Odds ratio > 4) 20. In addition, the right colon is 
often affected in patients with PSC and UC, a finding less commonly described in UC only 21. 
Rectal sparing and backwash ileitis are more frequent in patients with PSC and UC than in 
those with UC only leading to the assumption that UC in PSC might be a unique form of IBD 
22. A pathophysiological explanation for the increased risk of PSC patients to develop colonic 
dysplasia/malignancy has not yet been provided. Annual total colonoscopy with routine 
biopsies, however, is recommended in this group of patients for early detection of severe 
dysplasia and carcinoma.  
 
PREVIOUS THERAPEUTIC APPROACHES  
 
Numerous drugs have been evaluated for the treatment of PSC in randomized, controlled 
trials (e.g., colchicine, cyclosporine, methotrexate, d-penicillamine) and in pilot studies (e.g., 
budesonide, cladribin, etanercept, mycofenolate mofetil (MMF), nicotine, pentoxifylline, 
pirfenidone, prednisone, tacrolimus) and were mostly regarded as ineffective or were 
accompanied by major side effects during long-term treatment. None of these drugs is today 
recommended for monotherapy in PSC  1, 23.  
  
CURRENT THERAPEUTIC APPROACHES  
 
Ursodeoxycholic acid (UDCA) monotherapy is the only therapy in PSC for which 
improvement in serum liver tests has consistently been observed in placebo-controlled studies 
Beuers et al.: Future treatment of PSC 
 
 
4 
24-29, At doses of > 20 mg/kg/d of UDCA, surrogate markers of prognosis like the Mayo risk 
score have been shown to be improved in small cohorts of patients suggesting that “high dose 
UDCA” may represent an efficient treatment of PSC 29, 30. However, an obvious survival 
benefit with UDCA treatment has not been shown in PSC and no single study published so far 
fulfills the criteria of adequate sample size, adequate duration of follow-up and/or adequate 
dose of UDCA treatment in order to be able to prove or disprove a survival benefit of UDCA 
in PSC. The largest trial from Scandinavia analyzed data from 198 patients being treated over 
5 years with daily doses of 17-23 mg/kg. Unfortunately, this trial was underpowered (power 
analysis a priori: n=346), and the biochemical response of patients was unexpectedly poor 
when compared to smaller randomized, controlled trials using comparable doses of UDCA 24, 
26, 27, 29 . Data from a large randomized, long-term trial on “high dose UDCA” in PSC 
supported by the NIH have to be awaited before a firmer conclusion on the efficacy of “high 
dose UDCA” in PSC can be drawn. 
 
Interestingly, recent data suggest that UDCA treatment lowers the relative risk for PSC 
patients to develop hepatobiliary 31 and colonic dysplasia / carcinoma 32, 33 by yet unresolved 
mechanisms. Thus, UDCA treatment is considered as a treatment option in PSC by many 
experts although adequate prospective, randomized, controlled studies on long-term outcome 
are still lacking.  
 
The mechanisms and sites of action of UDCA in PSC and in cholestatic liver diseases in 
general are only in part resolved and await further elucidation 34. Stimulation of impaired 
hepatocellular (and cholangiocellular) secretion, detoxification of bile, and antiapoptotic 
effects both in hepatocytes and cholangiocytes are considered to contribute to its beneficial, 
mainly posttranscriptional effects in various cholestatic disorders 9, 12, 34-36. 
 
FUTURE THERAPEUTIC APPROACHES  
 
Novel bile acids and (other) nuclear receptor agonists ?  
 
Nuclear receptor agonists have recently been considered as potential partners for combination 
therapy with UDCA in cholestatic liver diseases. Nuclear receptors, like the pregnane X 
receptor (PXR; in humans also called steroid and xenobiotic receptor, SXR), the vitamin D 
receptor (VDR), the farnesoid-X receptor (FXR), the constitutive androstane receptor (CAR), 
and the peroxisome proliferator-activated receptors (PPARs) control the expression of 
numerous genes in liver and intestine involved in uptake (“phase 0” of biotransformation), 
biotransformation/detoxification (phase 1, 2) and secretion (phase 3) of exogenous and 
endogenous agents.  Some of these nuclear receptors (FXR, PXR, VDR) are activated, among 
others, by hydrophobic bile acids (e.g., chenodeoxycholic acid, lithocholic acid) whereas 
CAR is activated by bilirubin 12. Among exogenous ligands of these receptors, rifampicin and 
certain corticosteroids (PXR), Phenobarbital (CAR, PXR), fibrates (PPAR  /  ) and vitamin 
D (VDR) are in regular clinical use for various indications while others like 6-ethyl-CDCA 
(FXR) await further clinical evaluation.   
 
In PSC, PXR gene variants associated with a reduced PXR function had an increased risk of 
death or liver transplantation and a shorter median cumulative survival 37. PXR -/- mice show 
more extensive liver damage after bile duct obstruction than their wildtype littermates 11. 
These observations suggest that functional PXR is of critical importance under cholestatic 
conditions in man and mouse. 
 
Impaired small intestinal detoxification capacity as cofactor of carcinogenesis in PSC? 
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The apical sodium bile acid transporter (ASBT, synonymous: IBAT)  mediates uptake of bile 
acids from the intestinal lumen into the mucosa cells and is expressed not only in human 
ileocytes, but also at considerable levels in human duodenal mucosa 38. Thus, bile acids may 
enter not only ileocytes, but also duodenal and jejunal cells at considerable amounts, and may 
activate nuclear receptors like FXR, PXR, and VDR which stimulate induction of the small 
intestinal detoxification machinery. Induction of the intestinal detoxification machinery may, 
therefore, represent a so far unrecognized function of bile acids in the small intestine.  
 
In cholestasis, a relative deficit of hydrophobic bile acids and bilirubin in the intestinal lumen 
together with downregulation of the ASBT in the upper intestine 38 may lead to impaired 
stimulation of expression of key detoxification enzymes and related transporters in the small 
intestine. Consequently, colon mucosa cells as well as hepatocytes and cholangiocytes may be 
exposed to higher levels of potential exogenous co-carcinogens in cholestasis than under 
physiological conditions.  
 
Ursodeoxycholic acid (UDCA) exerts anticholestatic effects and improves biliary secretion of 
bile acids and bilirubin glucuronides in PSC 39. In man, UDCA is dehydroxylated to the 
potent PXR- and VDR-agonist lithocholic acid (LCA) by intestinal bacteria mainly in the 
colon 34. Recent data indicate that UDCA markedly lowers the relative risk for PSC patients 
to develop colonic dysplasia and colon carcinoma 32, 33 by yet unresolved mechanisms. 
 
We assume that cholestasis in patients with PSC and concomitant UC causes a relative deficit 
of hydrophobic bile acids and bilirubin glucuronides in the small and large intestinal lumen 
which might lead to impaired expression of the PXR-, VDR-, FXR- and CAR-triggered 
intestinal detoxification machinery and, thereby, impaired detoxification of putative 
carcinogens. Exposure of the right and left chronically inflamed (1st hit) colon in UC to an 
enhanced load of putative carcinogens from the small intestine (2nd hit) may predispose 
patients with PSC to the development of colonic dysplasia and carcinoma more than patients 
with UC only (only 1st hit) 20 or patients with other cholestatic liver diseases without 
underlying colon inflammation (only 2nd hit) 40.  
 
“High dose” UDCA and nuclear receptor agonists: activators of an impaired intestinal and 
hepatic detoxification capacity in PSC? 
 
UDCA might upregulate intestinal expression of proteins involved in biotransformation phase 
0, 1, 2, and 3 in patients with PSC and, thereby, reduce colon dysplasia/carcinoma risk by (a) 
reducing cholestasis and stimulating biliary secretion and intestinal content of endogenous 
bile acids and bilirubin and/or (b) inducing formation of the UDCA metabolite lithocholic 
acid (LCA), which is a potent PXR- and VDR-agonist. 
 
The medical treatment of patients with PSC (and associated inflammatory bowel disease, 
mainly UC) should aim at both, effects on the liver and the intestinal tract in order to reverse 
(i) the cholestatic hepatobiliary disorder and its sequelae, and (ii) the associated increased risk 
for malignant hepatobiliary and intestinal tumors. High dose UDCA may become the first 
promising treatment strategy in PSC for the above mentioned effects both on the hepatobiliary 
tract and the intestine. Derivatives of UDCA like its C23 analogue , norUDCA, may even be 
more effective than UDCA as demonstrated in an experimental animal model of cholestasis 
41, but studies in patients with cholestatic diseases like PSC are lacking so far.  
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Nuclear receptor agonists might complement the action of UDCA in the treatment of PSC by 
enhancing its anticholestatic effect at the site of the liver and by stimulating the small 
intestinal and hepatic detoxification machinery of biotransformation reactions phase 0 to 3. 
Therefore, various strategies including UDCA derivatives and agonists of the nuclear 
receptors FXR, PXR, VDR, and PPAR are discussed below for potential future medical 
therapy of patients with PSC.   
 
UDCA derivatives 
24-norUrsodeoxycholic acid (norUDCA) is the C23 homologue of the 3 ,7 -dihydroxy C24 
bile acid UDCA. In contrast to UDCA, norUDCA is barely amidated in liver cells and is 
mainly excreted into bile in its unconjugated and glucuronidated form. NorUDCA induces a 
bicarbonate-rich hypercholeresis mostly due to cholehepatic shunting of the unconjugated 
form 42. In a mouse model of a sclerosing cholangitis-like bile duct inflammation, the mdr2 -/- 
mouse, norUDCA was more effective than UDCA in improving serum liver tests and markers 
of inflammation and fibrosis, and inducing bile acid-detoxifying enzymes and transporters 41. 
The molecular mechanisms of action of norUDCA are under study at present. 
Pharmacokinetics of this bile acid were studied in humans in the past, and norUDCA was well 
tolerated 42. In the near future, norUDCA awaits further evaluation in healthy individuals and 
in patients with cholestatic liver disease, in particular PSC.  
Thus, norUDCA is a promising agent for evaluation for treatment of PSC.   
 
FXR agonists 
The nuclear hormone receptor farnesoid X receptor (FXR; NR1H4) is a bile acid-activated 
transcription factor that plays a critical role in bile acid homeostasis 43, 44. The hydrophobic 
bile acid chenodeoxycholic acid (CDCA) is the most potent natural activator of FXR, 
followed by deoxycholic acid (DCA) and lithocholic acid (LCA), whereas the hydrophilic bile 
acid, ursodeoxycholic acid (UDCA), appears to be only a weak agonist in man 44. In the liver, 
activation of FXR reduces uptake of bile acids and other cholephiles via repression of Na+-
taurocholate-cotransporting polypeptide (NTCP, SLC10A1) 45 and organic anion transporting 
protein (OATP1B1, SLCO1B1) 46 and downregulates bile acid synthesis via repression of the 
cytochrome P-450 enzymes CYP7A1 and CYP8B1 by an indirect mechanism involving 
nuclear receptor small heterodimer partner (SHP) 47. Conversely, FXR activates the 
canalicular secretion of bile acids and other constituents of bile via upregulation of the bile 
salt export pump (BSEP, ABCB11), the multidrug resistance-associated protein 2 (MRP2, 
ABCC2), the MDR3 P-glycoprotein (ABCB4) and the heteromeric organic solute transporter 
OSTα/OSTβ 12. FXR also stimulates the metabolism of hydrophobic bile acids and other toxic 
compounds to more hydrophilic and less toxic metabolites via upregulation of CYP3A4, 
which is involved in phase I hydroxylation reactions, and the uridine diphosphate 
glucuronosyl transferases UGT2B4 and UGT2B7, which form more water-soluble 
glucuronides 48, 49. In the small intestine, FXR negatively regulates the apical sodium-
dependent bile salt transporter (ASBT, SCL10A2) and stimulates expression of the ileal bile 
acid-binding protein (I-BAPB) and the basolateral efflux bile salt transporter OSTα/OSTβ 50-
53. Thus, FXR functions as a bile acid sensor and reduces their body load by decreasing their 
biosynthesis, and increasing their metabolism and hepatic and intestinal elimination. Based on 
these observations, FXR ligands may offer a rational treatment option for cholestatic liver 
diseases such as PSC. 
The potential beneficial effects of the potent and selective FXR agonist 6α-ethyl-
chenodeoxycholic acid (6-ECDCA), a semisynthetic bile acid derivative of CDCA, have been 
studied in in vivo rat models of cholestasis induced by lithocholic acid (LCA) or 17α-
ethynylestradiol (E217α). 6-ECDCA prevented bile flow impairment induced by both LCA 
and E217α and protected hepatocytes against acute necrosis caused by LCA 54, 55. In vivo 
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administration of 6-ECDCA led to enhanced expression of Shp, bsep, multidrug resistance-
associated protein-2, and multidrug resistance protein-2, while it repressed cyp7a1, cyp8b1 
and ntcp mRNA expression. These results were reproduced by another synthetic FXR ligand, 
the isoxazole GW4064 55. In primary cultures of human and rat hepatocytes, GW4064 
treatment increased SHP expression and decreased CYP7A1 expression 56. In bile duct–
ligation and α-naphthylisothiocyanate models of cholestasis, GW4064 treatment reduced 
markers of liver damage, inflammation and bile duct proliferation and was associated with 
decreased expression of biosynthetic genes and increased expression of genes involved in bile 
acid transport 57. Stimulation of the adaptive response to cholestasis by FXR agonists is likely 
to be beneficial in canalicular cholestasis, where secretory failure of the hepatocytes is the 
cause or in early partial/incomplete obstruction. In addition, an antifibrotic effect of FXR 
agonists has also been described 58.  
However, up-regulation of canalicular transporters by FXR ligands might be deleterious in 
advanced/complete obstruction. In support of this hypothesis, deletion of FXR in FXR 
knockout mice has been shown to reduce serum bile acids, biliary pressure, bile ductular 
proliferation, bile infarcts and mortality in response to bile duct ligation, suggesting a benefit 
of FXR inhibition in obstructive cholestasis 59, 60. Probable mechanisms for this protective 
effect include the downregulation of canalicular transporters, reducing biliary hydrostatic 
pressure, and the induction of basolateral Mrp4, facilitating “retrograde” secretion of bile 
acids and other potentially toxic cholephils into the systemic circulation for excretion by the 
kidney. Accordingly, FXR antagonists have also been proposed for the treatment of 
obstructive cholestasis 60. A unifying concept has not yet evolved and species differences 
make extrapolation to man difficult.  
Thus, FXR agonists may, at present, not be the first candidate for evaluation for long-term 
treatment of PSC. 
 
PXR agonists 
The pregnane X receptor (PXR; NR1I2) (32), another ligand-activated member of the nuclear 
receptor superfamily, also has a crucial role in regulating the expression of many genes 
involved in detoxification and metabolism of bile acids 61, including CYP3A4 and CYP7A1 
62, 63, SULT2A1 64, UGT1A3 and UGT1A4 65, MDR1 66, MRP2 67, and MRP3 68. Cholestatic 
PXR knockout mice exhibited more hepatic damage than wild-type mice both after bile duct 
ligation and cholic acid feeding, possibly due to impaired detoxification mechanisms and 
transport pathways 11, 60, 69. Activation of PXR may, therefore, be beneficial in cholestatic 
conditions. In line with this concept is the observation that the potent PXR ligand 5-pregnen-
3β-ol-20-one-16α-carbonitrile (PCN) dramatically reduced (litho-)cholic acid-induced liver 
injury in wild-type mice, but not in PXR knockout mice 63, 69. Hepatoprotection by PCN was 
associated with significant up-regulation of the basolateral bile acid efflux transporter MRP3, 
emphasizing the importance of alternative excretory routes for toxic bile acids as a protective 
mechanism contributing to bile acid homeostasis in cholestasis 69.  
Human PXR agonists include lithocholic acid, rifampicin, statins, dexamethasone and other 
corticosteroids, phenobarbital, and St. John wort12, The antibiotic rifampicin is a potent 
human PXR activator that is also being used to treat pruritus in cholestatic patients. 
Rifampicin has been reported to improve serum liver tests in PBC 70, 71. In otherwise healthy 
gallstone patients undergoing cholecystectomy, rifampicin induced upregulation of UGT1A1 
and MRP2 facilitating bilirubin elimination and increased CYP3A4 expression facilitating 
detoxification of bile acids 72. Consistent with this,  Dilger et al. showed that in patients with 
early stage PBC and healthy controls, rifampicin markedly induced CYP3A metabolism as 
assessed by pharmacokinetic profiling of budesonide and its phase 1 metabolites in plasma 
and urine and urinary 6β-hydroxy cortisol 73. The therapeutic bile acid ursodeoxycholic acid 
(UDCA) had no relevant effect on CYP3A metabolic activity 72, 73, but increased expression 
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of the hepatocyte transporters BSEP, MDR3, and MRP4 by posttranscriptional mechanisms 
72. These complementary effects on transcriptional regulation of hepatobiliary enzymes and 
transporters suggest that the combined use of both agents might have synergistic beneficial 
effects in patients with non-obstructive cholestasis. Rifampicin was reported to be safe in 
cholestatic liver disease during short-term use for up to two weeks 74. However, after use for 
more than 4 weeks, severe hepatotoxicity has been reported in up to 13% of patients with 
cholestatic disorders 71.  Thus, use of rifampicin for treatment of a chronic cholestatic liver 
disease like PSC, although conceptually attractive, may be limited by its rate of hepatotoxicity 
during long-term administration in cholestatic disorders.  
Combined treatment with UDCA and the PXR agonist atorvastatin at doses up to 40 mg 
daily 75 did not beneficially affect serum liver tests, but worsened serum alkaline phosphatase 
activity when compared to UDCA alone 76 in patients with early stage primary biliary 
cirrhosis who incompletely responded to UDCA monotherapy, This yet unexplained finding 
makes statins less attractive for future therapeutic evaluations in cholestatic disorders.  
The corticosteroid dexamethasone is a potent PXR and glucocorticoid receptor (GR) agonist, 
but is no treatment option for patients with PSC: the high rate of systemic side effects 
including induction of osteoporosis during long-term treatment prohibits use of 
dexamethasone in PSC. In addition, GR agonists have not been shown to be effective in most 
patients with PSC1, 23. Still, the effect of GR agonists may need to be better defined for 
subgroups particularly at young age and early stages of disease77. 
Budesonide is a potent corticosteroid with a high first-pass effect of about 90%. Budesonide 
is a PXR-78 and GR-agonist which might – in addition to its well-known anti-inflammatory 
action in the intestine 79 and the liver 73, 80-83 – lead to induction of  expression of key 
detoxification enzymes and transporters in the small intestine and the liver 78, 84. It might, 
thereby, at doses high enough to be an effective anti-inflammatory and inducing agent, but 
lower than those known to induce bone loss in cholestatic patients with early stage disease81, 
82 be an effective combination partner of UDCA.  Short-term treatment of PSC with 
budesonide and UDCA over a period of 8 weeks did not reveal a significant additional 
beneficial effect of budesonide on serum liver tests when compared to UDCA only 85. 
Treatment for 1 year revealed improvement of serum liver tests (alkaline phosphatase, AST) 
and of inflammatory activity around the bile ducts, but an increase of serum bilirubin in a 
heterogeneous group of PSC patients 86,  Thus, the PXR / GR agonist budesonide may 
deserve reevaluation at moderate doses in a well-defined subgroup of patients with early stage 
PSC and accompanying UC. 
  
VDR agonists 
The Vitamin D receptor (VDR, NR 1I1), a type 1 nuclear receptor, is commonly found in the 
intestine, bone and kidney of mammals. In response to its natural ligand 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3), VDR forms a complex with its heterodimer partner 
Retinoid X Receptor (RXR) and activates VDR response elements (VDREs) present in the 
regulatory region of target genes. Apart form the classical involvement of VDR in the 
regulation of genes required for calcium homeostasis and bone mineralization, VDR is also 
able to self-regulate its own transcription via a complex feedback mechanism involving the 
cytochrome P450 (CYP) genes. The CYP27B1 enzyme converts 25-hydroxyvitamin D 
(25(OH)D3) into 1,25(OH)2D3 via hydroxylation of carbon chains. Activation of VDR by 
1,25(OH)2D3, leads to the repression of CYP27B1 expression and thus a reduction in the VDR 
87. The VDR further activates CYP24A1, an enzyme whose role it is to inactivate 
1,25(OH)2D3, thereby resulting in a further reduction in VDR expression 88, 89.  
 
Recent in silico data has shown VDR to regulate over 27,000 genes in humans 90. A growing 
number of genes involved in bile formation, drug transport and drug metabolizing enzymes, 
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have been associated with regulation by VDR. The apical sodium-dependent bile acid 
transporter (ASBT) is responsible for bile acid absorption in the distal ileum 91, 92. In the 
presence of 1,25(OH)2D3, VDR was shown to activate rat ASBT leading to increased 
transport of taurocholate through the ileum 93.  
 
The multidrug resistance associated protein 3 (MRP3) mediates the basolateral efflux of 
organic anions and xenobiotic compounds in liver and intestine. Functional studies revealed 
VDR regulation of Mrp3 in the colon of mice exposed to vitamin D3 in addition to the 
secondary bile acid, lithocholic acid (LCA) 94. LCA, at high concentrations, is associated with 
colon cancer 95. Several mechanisms exist to detoxify LCA including its sulfation via the 
sulfotransferase enzyme SULT2A 96. Interestingly, increased activation of Mrp3 is associated 
with increased expression of Sult2a in mice, suggesting a key role for VDR in LCA 
detoxification 94. This is further supported by the VDR-mediated regulation of CYP3A genes 
97. CYP3A enzymes are involved in the catabolism of LCA in the intestine and liver. CYP3A4 
and CYP3A11 are induced by VDR in the presence of LCA 97. Indeed, competitive binding 
assays revealed LCA to be a direct ligand of VDR and in fact a more potent ligand for VDR 
than for the nuclear receptors FXR and PXR 97. 
 
A second bile acid and drug sulfating enzyme, SULT2A1, is also regulated by VDR 98. Most 
abundantly expressed in the intestine and liver, in vitro studies revealed a VDR mediated 
activation of SULT2A1 in the presence of 1,25(OH)2D3 98. While this study was carried out 
using the human hepatic cell line HepG2, several studies have shown VDR expression to be 
extremely low in human liver 99. Thus while intestinal SULT2A1 activation by the VDR is 
plausible, the induction of SULT2A1 in the liver remains controversial.  
 
Taken together, VDR may represent a promising therapeutic target in early stage PSC 
considering potential improvement of mainly intestinal detoxification capacity by 
administration of VDR agonists.  
 
PPAR agonists 
Peroxisome proliferator-activated receptors (PPARs) are transcription factors that are 
activated by various ligands, heterodimerize with retinoid X receptors and bind to peroxisome 
proliferator response elements in the promoter regions of their respective target genes. Three 
PPAR genotypes (         have been described and all of them are expressed in the 
vasculature and inflammatory cells 100. 
PPAR  is also expressed in the liver and has been implicated in the beta oxidation of fatty 
acids as well as lipid metabolism. PPAR  is activated by natural ligands such as fatty acids as 
well as fibrates, a class of drugs that are commonly used to lower lipids 101. Interestingly, 
bezafibrate has been shown to have additional beneficial effects on cholestatic liver enzymes 
(aP,  -GT) in patients with primary biliary cirrhosis (PBC) already receiving UDCA 
monotherapy, although these trials are rather small 102-104. How can these clinical observations 
be explained?   
PPARα agonists decrease IL-1-induced CRP expression in primary human hepatocytes and 
induction of plasma CRP levels by IL-1 in human CRP-expressing transgenic mice 105, 106. In 
these human CRP transgenic mice, PPARα activation also reduced basal plasma CRP levels 
even in the absence of an inflammatory stimulus. Thus, fibrates might attenuate the 
inflammation of bile ducts via PPARα activation in PBC as its major mechanism of action. 
Since PSC is characterized by chronic inflammation of the small and large bile ducts which 
ultimately causes the typical bile duct strictures leading to cirrhosis, fibrates or novel PPARα 
agonists might be an attractive treatment option in addition to UDCA also or even more so for 
PSC patients. 
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Fenofibrate has recently been shown to suppress tumor growth by inhibition of angiogenesis, 
which makes this drug even more interesting as a potential treatment option in PSC, since 
PSC is associated with a greatly increased tumor risk as outlined earlier 107. Moreover, 
PPARα activates transcription of the human ASBT (SLC10A2) gene 108.  
PPARγ is important in the regulation of glucose metabolism and cell growth processes and is 
known to inhibit the production of proinflammatory cytokines 109. Pharmacologically, PPARγ 
is targeted by thiazolidinediones which are used in the treatment of diabetes mellitus. 
Pioglitazone has also been shown to improve metabolic parameters and histology in patients 
with non-alcoholic steatohepatitis 110. Interestingly, PPARγ protein is ubiquitously expressed 
in intrahepatic biliary epithelium of PBC patients, but is reduced in damaged bile ducts 111. 
Thus, PPARγ might be important to maintain homeostasis in the intrahepatic biliary 
epithelium.  
Fickert et al. recently hypothesized that PSC might represent the "arteriosclerosis of the bile 
duct" initiated by toxic biliary lipids and demonstrated puzzling similarities of molecular 
pathomechanisms involved in these vascular and biliary entities 112. As outlined in this 
provocative hypothesis paper, exposure to abnormal luminal lipid composition, ultimately 
resulting in lipid oxidation, might be critically involved in both conditions.  
Taken together, these concepts could stimulate research on the role of PPAR agonists in the 
treatment of PSC. 
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